北京盈科（厦门）律师事务所 关于 三达膜环境技术股份有限公司 2023 年第二次临时股东大会的 法律意见书 www.yingkelawyer.com 福建省厦门市思明区鹭江道 2 号厦门第一广场 25 楼（361001） 电话：0592-2936688 传真：0592-2525625 关于三达膜环境技术股份有限公司 2023 年第二次临时股东大会的 法律意见书 致：三达膜环境技术股份有限公司 北京盈科（厦门）律师事务所（以下简称"本所"）接受三达膜环境技术股份有 限公司（以下简称"公司"）的委托，依据《中华人民共和国公司法》（以下简称"《公 司法》"）《中华人民共和国证券法》（以下简称"《证券法》"）中国证券监督管理 委员会《上市公司股东大会规则（2022年修订）》（以下简称"《股东大会规则》"） 等法律、法规和其他规范性文件以及《三达膜环境技术股份有限公司章程》（以下 简称"《公司章程》"）的有关规定，指派律师出席了公司的2023年第二次临时股东 大会（以下简称"本次股东大会"），并就本次股东大会相关事项出具本法律意见书。 为出具本法律意见书，本所律师审查了公司本次股东大会的有关文件和材料。 本所及本所律师 ...

重要内容提示： 证券代码：688101 证券简称：三达膜 公告编号：2023-026 三达膜环境技术股份有限公司 2023 年第二次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2023 年 8 月 9 日 （二） 股东大会召开的地点：福建省厦门市集美区锦亭北路 66 号三达科技园办 公楼三层 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 7 | | --- | --- | | 普通股股东人数 | 7 | | 2、出席会议的股东所持有的表决权数量 | 238,197,767 | | 普通股股东所持有表决权数量 | 238,197,767 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比例（%） | 71.3423 | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 71.3423 | （四） 表决方 ...

证券代码：688101 证券简称：三达膜 公告编号：2023-020 三达膜环境技术股份有限公司 关于参加"2023 年陕西辖区上市公司投资者集体接待 日暨 2022 年度业绩说明会"的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 为促进上市公司规范运作、健康发展，增强上市公司信息透明度， 加强与广大投资者沟通交流，进一步提升投资者关系管理水平，陕西 上市公司协会根据陕西证监局工作部署，联合深圳市全景网络有限公 司举办"2023年陕西辖区上市公司投资者集体接待日暨2022年度业绩 说明会活动"。 届时，公司董事长及相关高管人员将通过互动平台与投资者进行 网络沟通和交流。为充分尊重投资者、提升交流的针对性，现就公司 2022年度业绩说明会提前向投资者公开征集问题，广泛听取投资者的 意见和建议。投资者可于2023年5月15日（星期一）16：00前访问"全 景路演"（https://rs.p5w.net），进入问题征集专题页面。公司将在 2022年度业绩说明会上，对投资者普遍关注的问题进行回答。欢迎广 大投资者积极参与 ...

Financial Performance - The company's operating revenue for Q1 2023 was CNY 203,109,663.47, representing a year-on-year increase of 23.62% compared to CNY 164,000,000 in the same period last year[5]. - Net profit attributable to shareholders was CNY 49,108,334.49, a decrease of 15.60% year-on-year due to a significant decline of 65.50% in investment income from joint ventures[6]. - The net profit after deducting non-recurring gains and losses was CNY 39,913,711.05, down 19.8% year-on-year[5]. - The basic and diluted earnings per share were both CNY 0.15, reflecting a decrease of 11.76% compared to the previous year[6]. - Operating profit for Q1 2023 was RMB 55,844,727.14, a decrease of 10.5% from RMB 62,425,331.75 in Q1 2022[20]. - The total profit for Q1 2023 was RMB 56,426,448.96, a decrease of 13.9% from RMB 65,515,548.82 in Q1 2022[21]. Research and Development - Research and development expenses totaled CNY 11,669,585.90, accounting for 5.75% of operating revenue, a decrease of 0.44 percentage points year-on-year[6]. - Research and development expenses increased to RMB 11,669,585.90 in Q1 2023, up from RMB 10,169,998.91 in Q1 2022, reflecting a growth of 14.7%[20]. Cash Flow and Assets - Cash flow from operating activities showed a net outflow of CNY 41,442,358.53, primarily due to a decrease in advance payments related to membrane technology projects[6]. - Cash flow from operating activities for Q1 2023 was negative at RMB -41,442,358.53, compared to a positive RMB 14,571,468.67 in Q1 2022[23]. - The company's cash and cash equivalents decreased to RMB 692,894,202.13 from RMB 1,360,139,480.12, representing a decline of approximately 49.1%[15]. - Total cash and cash equivalents at the end of Q1 2023 were RMB 690,483,840.83, down from RMB 812,910,269.91 at the end of Q1 2022[24]. - The company reported a significant increase in investment cash outflow to RMB 615,828,158.36 in Q1 2023, compared to RMB 503,825,698.25 in Q1 2022[24]. Shareholder Information - The top two shareholders, San Da Membrane Technology (Singapore) Co., Ltd. and Qingyuan (China) Co., Ltd., hold 43.36% and 25.66% of the shares, respectively[11]. Balance Sheet Highlights - The company's total assets at the end of the reporting period were CNY 5,279,643,919.07, a slight decrease of 0.36% from the end of the previous year[6]. - As of March 31, 2023, the company's total assets amounted to RMB 5,279,643,919.07, a slight decrease from RMB 5,298,919,980.32 at the end of 2022[16]. - Accounts receivable increased to RMB 702,677,625.98 from RMB 661,336,677.21, showing a growth of about 6.3%[15]. - Inventory rose to RMB 866,974,480.82 from RMB 832,415,574.87, indicating an increase of approximately 4.2%[15]. - Total current liabilities decreased to RMB 1,229,800,316.81 from RMB 1,307,636,939.38, reflecting a reduction of about 5.9%[17]. - The company's total equity increased to RMB 3,649,226,468.95 from RMB 3,598,054,979.68, marking a growth of approximately 1.4%[17]. - The long-term equity investments rose to RMB 381,944,687.60 from RMB 375,646,718.73, an increase of about 1.7%[16]. - The company's contract liabilities increased to RMB 702,861,033.06 from RMB 680,517,495.79, representing a growth of approximately 3.2%[17]. - The total non-current liabilities increased to RMB 400,617,133.31 from RMB 393,228,061.26, indicating an increase of about 1.9%[17]. - The company's retained earnings rose to RMB 1,634,107,704.61 from RMB 1,584,999,370.12, reflecting an increase of approximately 3.1%[17]. Government Subsidies - The company received government subsidies amounting to CNY 4,784,551.55, which are closely related to its normal business operations[9].

证券代码：688101 证券简称：三达膜 公告编号：2023-019 三达膜环境技术股份有限公司 关于召开 2022 年度暨 2023 年第一季度业绩暨现金 分红说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 重要内容提示： 会议召开时间：2023 年 05 月 12 日（星期五）下午 13:00-14:00 会议召开地点：上海证券交易所上证路演中心（网址： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络文字互动问答 投资者可于 2023 年 05 月 05 日（星期五）至 05 月 11 日（星期 四）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或 通过公司邮箱（ir@suntar.com）进行提问。公司将在说明会上对投 资者普遍关注的问题进行回答。 三达膜环境技术股份有限公司（以下简称"公司"）已于 2023 年 04 月 20 日发布公司 2022 年年度报告及关于公司 2022 年度拟不进行 利润分配专项说明的公告，于 2023 年 04 ...

Financial Performance - The net profit attributable to shareholders for 2022 was CNY 217,902,483.86, with undistributed profits amounting to CNY 1,584,999,370.12[5]. - The company achieved operating revenue of CNY 1,259,160,685.98 in 2022, representing a year-on-year increase of 9.42%[24]. - Net profit attributable to shareholders was CNY 217,902,483.86, a decrease of 11.82% compared to the previous year[24]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 186,487,630.01, down 14.63% year-on-year[24]. - The net cash flow from operating activities increased by 11.85% to CNY 247,329,288.25[24]. - The company's total assets reached CNY 5,298,919,980.32 at the end of 2022, a 9.15% increase from the previous year[24]. - Basic earnings per share decreased to CNY 0.65, down 12.16% from CNY 0.74 in 2021[25]. - The R&D expenditure accounted for 4.83% of operating revenue, an increase of 0.29 percentage points compared to the previous year[25]. - The weighted average return on net assets was 6.24%, a decrease of 1.16 percentage points from 2021[25]. - The company reported a significant decline in investment income from joint ventures compared to the previous year, contributing to the decrease in net profit[25]. Dividend Policy - The company plans to not distribute cash dividends, issue bonus shares, or convert reserves into share capital for the 2022 fiscal year, opting to carry forward undistributed profits to the next year[5]. - The company has a cash dividend policy that prioritizes cash dividends, with a minimum distribution ratio of 80% for mature companies without major capital expenditures[193]. - The company’s cash dividend policy is designed to protect the rights of minority investors, ensuring transparency and compliance with regulations[195]. Governance and Compliance - The report includes a standard unqualified audit opinion from Rongcheng Accounting Firm, ensuring the accuracy and completeness of the financial statements[5]. - The company has confirmed that all board members were present at the board meeting, ensuring proper governance and oversight[5]. - There are no special arrangements for corporate governance that apply to the company[8]. - The company has established a governance structure that complies with relevant laws and regulations, ensuring effective operation and risk management[145]. - The company maintains transparent information disclosure practices, ensuring all investors have equal access to information[148]. - The company’s governance structure complies with relevant laws and regulations, ensuring the legality of meeting procedures and voting results[154]. - The company has not faced any penalties from securities regulatory agencies in the past three years[175]. - The internal control system is strictly implemented, with regular audits conducted by the audit department to ensure compliance and effective execution of internal controls[198]. - The internal control audit report received a standard unqualified opinion, indicating no significant deficiencies were found during the evaluation[199]. Research and Development - The company is actively engaged in research and development of graphene membranes, which are anticipated to enhance performance in water purification applications[15]. - The total R&D investment for the year was approximately ¥60.82 million, representing a 16.47% increase from the previous year's ¥52.21 million, with R&D expenses accounting for 4.83% of total revenue[75]. - The company has applied for a total of 334 patents, including 200 invention patents, 132 utility model patents, and 2 design patents, with 187 patents granted as of December 31, 2022[72]. - The company has established a comprehensive R&D platform based on the "RDPA" system, focusing on research, development, pilot testing, and application[64]. - The company is committed to expanding its R&D efforts as a key part of its growth strategy, supported by institutional guarantees and innovation incentives[64]. - The company has emphasized the importance of intellectual property and patent technology applications, with 32 new patents filed during the reporting period[71]. Operational Strategy - The company is exploring new business models, including Build-Operate-Transfer (BOT) and Transfer-Operate-Transfer (TOT), to enhance operational efficiency and service delivery[15]. - The company has developed a range of membrane products including tubular ceramic membranes, spiral membranes, flat membranes, hollow fiber membranes, and composite ceramic nanofiltration cores, which are widely used in various industries such as pharmaceuticals, food and beverage, and environmental protection[40]. - The company’s business model includes various operational strategies such as EPC, BOT, BT, and TOT, allowing flexibility in meeting user requirements[46]. - The company provides integrated membrane technology solutions, generating revenue through sales of membrane materials, components, and systems, with a focus on long-term stable income from consumable parts[47]. - The company is committed to improving customer satisfaction by optimizing process flows and reducing operational costs through technology upgrades[142]. Market and Industry Trends - The membrane technology application industry is expected to maintain a high gross margin level due to strong market demand and high technical barriers[54]. - The domestic membrane industry is expected to see an increase in application levels and expansion into new fields, driven by advancements in domestic membrane material technology[60]. - The company aims to expand its market presence through innovative water treatment solutions and strategic partnerships in the environmental technology sector[15]. - The market for industrial wastewater reuse is expected to grow by 20% annually, driven by environmental and clean production requirements[138]. - The municipal drinking water purification market is projected to grow at an annual rate of over 15% due to ongoing improvements in municipal water quality[138]. Risks and Challenges - The company has detailed various operational risks and corresponding mitigation measures in the report, emphasizing the importance of risk management[4]. - The company faces risks in market expansion due to differing local policies and intense competition in new markets[94]. - The company’s revenue is closely tied to macroeconomic conditions and environmental policies, which can lead to income volatility[97]. - Accounts receivable are subject to risks due to slow payment from downstream customers and local government financial conditions affecting wastewater treatment fees[93]. - The company is facing risks related to the economic benefits of its fundraising projects, which may not meet expectations due to market environment changes and project delays[104]. Employee and Management - The total number of employees in the parent company and major subsidiaries is 1,159, with 668 in production, 61 in sales, 224 in technology, and 45 in finance[188]. - The company has established a scientific and fair compensation mechanism based on the importance and scarcity of positions, ensuring employee stability and satisfaction[190]. - Total remuneration for all directors, supervisors, and senior management at the end of the reporting period amounted to 478.48 million[171]. - The company has implemented a training and development management system to enhance employee skills and promote sustainable development[191]. - The management team includes experienced professionals with extensive backgrounds in investment and technology sectors, contributing to strategic decision-making[170]. Sustainability and ESG - The company emphasizes the importance of ESG, integrating it into its core business operations, viewing it as a cornerstone for sustainable and long-term development[200]. - The company is committed to green development, focusing on pollution prevention, waste reduction, and energy conservation as part of its operational strategy[200]. - The company aims to establish a high-efficiency, clean, low-carbon, and circular green factory as part of its long-term development strategy[200].

Financial Performance - The net profit attributable to shareholders for 2022 was CNY 217,902,483.86, with undistributed profits amounting to CNY 1,584,999,370.12[5]. - The company achieved operating revenue of CNY 1,259,160,685.98 in 2022, representing a year-on-year increase of 9.42%[24]. - Net profit attributable to shareholders was CNY 217,902,483.86, a decrease of 11.82% compared to the previous year[24]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 186,487,630.01, down 14.63% year-on-year[24]. - The net cash flow from operating activities increased by 11.85% to CNY 247,329,288.25, mainly due to increased cash received from sales of goods and services[24]. - The company's total assets at the end of 2022 were CNY 5,298,919,980.32, reflecting a 9.15% increase from the previous year[24]. - The weighted average return on net assets decreased to 6.24%, down 1.16 percentage points from the previous year[25]. - Research and development expenses accounted for 4.83% of operating revenue, an increase of 0.29 percentage points compared to the previous year[25]. Corporate Governance - The board of directors and management have confirmed the accuracy and completeness of the financial report, with no significant omissions or misleading statements[4]. - The report emphasizes the importance of corporate governance and the presence of all board members during the meeting[5]. - The company has established a governance structure that complies with relevant laws and regulations, ensuring effective operation and risk management[145]. - The company maintains transparent information disclosure practices, ensuring all investors have equal access to information[148]. - All proposals at the five shareholder meetings held in 2022 were approved without any rejections[154]. - The company held its first extraordinary general meeting on January 17, 2022, to elect members of the board and supervisory committee[152]. - The annual general meeting on May 11, 2022, approved the 2021 annual report and financial statements[152]. - The company has established specialized committees under the board, including the audit committee and the nomination committee, to enhance governance[180]. Research and Development - The company is actively engaged in research and development of graphene membranes, which are anticipated to enhance performance in water treatment applications[15]. - The company has over 20 R&D projects completed during the reporting period, indicating a strong focus on innovation[36]. - The total R&D investment for the year was approximately ¥60.82 million, an increase of 16.47% from the previous year's ¥52.21 million, representing 4.83% of total revenue[75]. - The company applied for a total of 334 patents by December 31, 2022, including 200 invention patents, and received 187 authorized patents, with 184 remaining valid after three expired[72]. - The company has developed advanced inorganic non-metallic membrane materials with independent intellectual property rights, which can replace imported products and offer superior performance[46]. - The company has established a strong market influence and authority in the membrane technology application field, with significant experience in industrial liquid separation and membrane water treatment[87]. Operational Risks and Mitigation - The company has outlined various operational risks and corresponding mitigation strategies in the report[4]. - The report includes a forward-looking statement risk declaration, indicating that future strategies and plans are subject to investment risks[6]. - The company has not engaged in any non-operational fund occupation by controlling shareholders or related parties[7]. - There are no violations of decision-making procedures regarding external guarantees[7]. - The company faces risks from changes in major customers' production expansion needs, which can lead to fluctuations in operational performance[93]. - The company's revenue is closely tied to macroeconomic conditions and environmental policies, making it susceptible to fluctuations in market demand[97]. Sustainability and Environmental Impact - The company is committed to sustainable practices, aiming to reduce the environmental impact of its operations through innovative technologies[14]. - The company emphasizes the importance of ESG, integrating it into its core business operations, viewing it as a cornerstone for sustainable development[200]. - The company is actively pursuing low-carbon goals and aims to establish efficient, clean, and circular green factories[200]. - The company has implemented a management system audit and energy-saving certification to enhance operational efficiency[200]. Market Position and Growth Strategy - The anticipated growth in the municipal and industrial wastewater treatment sectors is expected to drive revenue growth in the coming years[15]. - The company is exploring strategic partnerships and potential acquisitions to bolster its market position and technological capabilities[16]. - The company aims to enhance its market position through continuous innovation and the development of proprietary technologies in the membrane sector[62]. - The company plans to leverage its experience and brand advantage in membrane technology to create a comprehensive membrane industry chain covering materials, components, equipment, software, and applications[139]. - The company will focus on international market expansion, particularly in Southeast Asia, by enhancing its sales team and recruiting talent[143]. Employee and Management Structure - The total number of employees in the parent company and major subsidiaries is 1,159, with 668 in production, 61 in sales, 224 in technology, and 45 in finance[188]. - The company has established a scientific and fair compensation mechanism based on job importance and scarcity, ensuring employee stability and satisfaction[190]. - Total remuneration for all directors, supervisors, and senior management at the end of the reporting period amounted to 478.48 million[171]. - The company has expanded its leadership team with individuals holding key positions across multiple subsidiaries, enhancing its operational capabilities[169]. Financial Management - The company plans to utilize remaining fundraising for permanent working capital after project completions[105]. - The company has adjusted the implementation content and postponed the Singapore R&D center project to March 2024 due to public health safety controls[103]. - The company has established a strict management system for subsidiaries, ensuring compliance with regulations and timely decision-making[198]. - The company has implemented a remuneration scheme for directors and senior management based on actual operating conditions[171].

2022 年第三季度报告 证券代码：688101 证券简称：三达膜 三达膜环境技术股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人 LAN WEIGUANG、主管会计工作负责人唐佳菁及会计机构负责人（会计主管人 员）庄毅斌保证季度报告中财务信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期 | 年初至报告期末 | 年初至报告期 | | --- | --- | --- | --- | --- | | | | 比上年同 | | 末比上年同期 | | | | 期增减变 | | 增减变动幅度 | | | | 动幅度(%) | | (%) | | 营业收入 | 307,118,640.10 | 4 ...

Financial Performance - The company reported a total revenue of RMB 500 million for the first half of 2022, representing a year-on-year increase of 15%[1]. - The company has set a revenue guidance of RMB 1.2 billion for the full year 2022, reflecting an expected growth of 10%[1]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the first half of 2022, representing a 15% year-over-year growth[13]. - The company has set a future outlook with a revenue target of 2.5 billion RMB for the full year 2022, which would require a 10% increase in the second half[13]. - The gross profit margin for the first half of 2022 was reported at 45%, an increase from 40% in the same period last year[13]. - The company achieved operating revenue of CNY 441.81 million in the first half of 2022, an increase of 9.58% compared to the same period last year[19]. - Net profit attributable to shareholders decreased by 16.42% to CNY 111.72 million, primarily due to delays in project acceptance caused by the ongoing COVID-19 pandemic[19]. - The net profit after deducting non-recurring gains and losses was CNY 95.68 million, down 21.51% year-on-year[19]. - The net cash flow from operating activities increased by CNY 10.01 million, compared to a negative cash flow of CNY 8.18 million in the same period last year[19]. - The total assets of the company have increased to 3 billion RMB, reflecting a 12% growth compared to the previous year[13]. User Growth - User data indicates a growth in the customer base, with an increase of 20% in active users compared to the same period last year[1]. - User data indicates a growth in active users, with a 20% increase compared to the previous year, reaching 500,000 active users[13]. Product Development - New product development includes the launch of a high-efficiency membrane technology, projected to increase production capacity by 30%[1]. - New product development includes the introduction of a graphene membrane technology, which is expected to enhance water treatment efficiency by 30%[12]. - The company has invested RMB 50 million in R&D for new membrane materials, aiming for a 15% improvement in separation efficiency[1]. - The company is investing 100 million RMB in R&D for new filtration technologies over the next two years[12]. Market Expansion - The company plans to expand its market presence in Southeast Asia, targeting a 25% market share by the end of 2023[1]. - The company plans to expand its market presence in Southeast Asia, targeting a 25% market share in the region by 2025[12]. - A strategic acquisition of a local competitor is in progress, expected to enhance the company's technological capabilities and market reach[1]. - A strategic acquisition of a local water treatment firm is anticipated to be completed by Q3 2022, expected to add 300 million RMB in annual revenue[12]. Operational Efficiency - The company has implemented new operational strategies to improve cost efficiency, targeting a reduction in operational costs by 5%[1]. - The company aims to reduce operational costs by 15% through improved management practices and technology upgrades[12]. Research and Development - The company has established a "RDPA" R&D system focused on membrane technology applications, emphasizing the development and improvement of membrane materials and wastewater treatment processes[38]. - The company collaborates with government, universities, and research institutions to enhance its innovation capabilities and address common and key technologies in membrane material development[39]. - The company achieved a total R&D investment of ¥22,057,008.13, representing a 20.37% increase compared to ¥18,324,015.19 in the previous year[57]. - The total R&D investment accounted for 4.99% of the operating revenue, an increase of 0.45 percentage points from 4.54%[57]. - The company has a strong focus on expanding its R&D capabilities as a key competitive advantage[54]. Environmental Compliance - The company has established a comprehensive environmental management system to oversee its wastewater treatment operations across various regions[116]. - The company’s wastewater treatment facilities are equipped with advanced pollution control technologies to meet regulatory requirements[116]. - The company is committed to maintaining its status as a responsible environmental steward by adhering to all applicable pollution discharge standards[116]. - The company has implemented continuous monitoring and reporting of wastewater discharge metrics to maintain compliance with national standards[121]. Shareholder Commitments - The company has committed to not transferring or managing shares for 36 months post-IPO, ensuring stability in shareholding[132]. - The company reported a commitment to long-term holding of shares, indicating a positive outlook on the industry and the company's future development prospects[135]. - The company stated that during the lock-up period, it will not reduce its holdings in the company’s shares, adhering to legal and regulatory requirements[135]. - The company will ensure that any share reductions will not be below the initial offering price[135]. Legal and Regulatory Matters - The company received a regulatory warning from the Shanghai Stock Exchange regarding the improper use of raised funds, including using part of the excess funds for working capital without board approval[150]. - The company reported a civil lawsuit involving a contract dispute with a claim amount of ¥15,775,097.40, which was resolved through a mediation agreement[149]. - The company successfully appealed an administrative penalty, resulting in a court ruling that favored the company, which will positively impact its operations[149]. - The company has implemented measures to ensure compliance with regulations regarding the use of raised funds and will improve its management practices[150].

Financial Performance - Operating revenue for Q1 2022 was CNY 164,304,322.88, an increase of 2.78% compared to the same period last year[3] - Net profit attributable to shareholders was CNY 58,181,871.82, a decrease of 7.99% year-on-year[3] - Basic earnings per share for the period was CNY 0.17, down 8.28% from the previous year[4] - The weighted average return on equity was 1.68%, a decrease of 0.22 percentage points[4] - Net profit for Q1 2022 was ¥59.48 million, a decrease of 6.3% compared to ¥63.79 million in Q1 2021[20] - The company reported a total profit of ¥65.52 million in Q1 2022, down from ¥70.61 million in Q1 2021[20] Research and Development - R&D investment totaled CNY 10,169,998.91, representing 6.19% of operating revenue, an increase of 1.19 percentage points[4] - Research and development expenses rose to ¥10.17 million in Q1 2022, up 27.3% from ¥7.99 million in Q1 2021[19] Cash Flow and Liquidity - Net cash flow from operating activities was CNY 14,571,468.67, with a significant increase attributed to the commencement of several large-scale membrane technology projects[8] - Cash flow from operating activities generated a net inflow of ¥14.57 million in Q1 2022, compared to a net outflow of ¥33.74 million in Q1 2021[22] - Cash and cash equivalents were reported at CNY 824,765,526.69, down from CNY 1,231,756,309.30, representing a decrease of approximately 33%[15] - Cash and cash equivalents at the end of Q1 2022 were ¥812.91 million, down from ¥916.02 million at the end of Q1 2021[22] Assets and Liabilities - Total assets at the end of the period were CNY 4,917,615,979.17, an increase of 1.30% from the end of the previous year[4] - The company's total current assets reached CNY 2,918,169,336.98, compared to CNY 2,865,673,755.51 in the previous year, indicating an increase of about 1.8%[16] - The company's total liabilities stood at CNY 1,379,494,042.27, slightly up from CNY 1,375,985,512.15, showing a marginal increase of about 0.1%[17] - The total equity attributable to shareholders was CNY 3,492,640,608.52, an increase from CNY 3,434,458,736.70, reflecting a growth of approximately 1.7%[17] - The company's inventory increased to CNY 677,673,899.73 from CNY 591,767,853.70, marking a rise of about 14.5%[16] - The accounts receivable decreased slightly to CNY 559,366,463.44 from CNY 570,034,482.96, indicating a decline of approximately 1.8%[15] - The company’s non-current assets totaled CNY 1,999,446,642.19, a slight increase from CNY 1,988,958,222.42, reflecting a growth of about 0.5%[16] - The company’s total liabilities and equity amounted to CNY 4,917,615,979.17, consistent with the total assets reported[18] Shareholder Information - The total number of ordinary shareholders at the end of the period was 14,331[10] - The largest shareholder, Sanda Membrane Technology (Singapore) Co., Ltd., held 43.36% of the shares[11] Financial Standards and Governance - The company has implemented new accounting standards starting from 2022, affecting the financial statements from the beginning of the year[23] - The board of directors held a meeting on April 28, 2022, to discuss the quarterly report[24]